Venetoclax added to ibrutinib in patients with CLL with molecular resistance to BTKi treatment [Video]

Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses the initial results of a study in patients with chronic lymphocytic leukemia (CLL), which investigated whether the addition of venetoclax to ibrutinib could overcome molecular resistance to BTK inhibitor (BTKi) treatment, improving patient outcomes and reducing the likelihood of progressive disease. The findings of the ongoing study have been encouraging, as the combination of venetoclax and ibrutinib resulted in a level of BTK C481S mutation below the detectable limit in almost two-thirds of patients and allowed over one-third of patients to stop treatment as a result of reaching deep remission or a partial response. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.